Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as PD-L1 and tumor mutational burden. New biomarkers are neede...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranganath, Harsha, Jain, Amit L., Smith, Justin R., Ryder, Julie, Chaudry, Amina, Miller, Emily, Hare, Felicia, Valasareddy, Poojitha, Seitz, Robert S., Hout, David R., Varga, Matthew G., Schweitzer, Brock L., Nielsen, Tyler J., Mullins, Janice, Ross, Douglas T., Gandara, David R., Vidal, Gregory A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008990/
https://www.ncbi.nlm.nih.gov/pubmed/35421940
http://dx.doi.org/10.1186/s12885-022-09470-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008990/
https://www.ncbi.nlm.nih.gov/pubmed/35421940
http://dx.doi.org/10.1186/s12885-022-09470-y

Ejemplares similares